In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 177-197

  Meltzer, Herbert Y ^a   Huang, Mei ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antipsychotic; clozapine; dopamine; haloperidol; microdialysis; schizophrenia; serotonin

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; AMISULPRIDE; AMPEROZIDE; ARIPIPRAZOLE; ASENAPINE; BIFEPRUNOX; CHLORPROMAZINE; CLOZAPINE; EPLIVANSERIN; FLUPERLAPINE; HALOPERIDOL; ILOPERIDONE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PIMAVANSERIN; PLACEBO; PRAZOSIN; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; THIORIDAZINE; TIOSPIRONE; TIOTIXENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

ADJUVANT THERAPY; ANATOMY; BINDING AFFINITY; CATALEPSY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOPAMINERGIC SYSTEM; DRUG PROTEIN BINDING; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN FUNCTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; DOPAMINE; HALLUCINOGENS; HUMANS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PROLACTIN; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 50349096587     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00909-6     Document Type: Review

References (166)

1. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 169 2 (2006) 263-273
2. Ahlenius S. Antipsychotic-like properties of the 5-HT1A agonist 8-OH-DPAT in the rat. Pharmacol. Toxicol. 64 1 (1989) 3-5
3. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., Tumuklu M., Yazici M.K., Alptekin K., Ertugrul A., Jayathilake K., Gogus A., Tunca Z., and Meltzer H.Y. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 66 (2005) 63-72
4. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
5. 2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural. Transm. Gen. Sect. 85 (1991) 19-29
6. 2A receptor gene. Lancet 346 8970 (1995) 281-282
7. 2A receptor gene and response to clozapine. Mol. Psychiatry 3 1 (1998) 61-66
8. 2A receptors and clozapine response. Schizophr. Res. 32 2 (1998) 93-99
9. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 71 (2003) 127-131
10. Bakshi V.P., and Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283 (1997) 666-674
11. Barbato L., Monge A., Stocchi F., and Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct. Neurol. 11 4 (1996) 201-207
12. Barker E.L., Westphal R.S., Schmidt D., and Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269 (1994) 11687-11690
13. 6 receptor. J. Neurochem. 71 5 (1998) 2169-2177
14. Bonaccorso S., Meltzer H.Y., Li Z., Dai J., Alboszta A.R., and Ichikawa J. SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27 (2002) 430-441
15. Bortolozzi A., Amargos-Bosch M., Adell A., Diaz-Mataix L., Serrats J., Pons S., and Artigas F. In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT (2A) receptors: effect of antipsychotic drugs. Eur. J. Neurosci. 18 (2003) 1235-1246
16. Bortolozzi A., Diaz-Mataix L., Scorza M.C., Celada P., and Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95 (2005) 1597-1607
17. Bruins Slot L.A., Kleven M.S., and Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 7 (2005) 996-1006
18. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15 (1996) 442-455
19. 2 receptors. J. Pharmacol. Exp. Ther. 302 1 (2002) 381-389
20. 3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
21. 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J. Neural. Transm. 106 (1999) 123-129
22. 1A receptor agonism. Brain Res. 1023 (2004) 54-63
23. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol. Neurobiol. 26 4-6 (2006) 365-384
24. 2 receptors?. Pharmacol. Biochem. Behav. 36 (1990) 901-906
25. Dawson L.A., Nguyen H.Q., and Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001) 662-668
26. Dawson L.A., Nguyen H.Q., and Li P. Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist. Brain Res. Bull. 59 (2003) 513-521
27. Dean B., Hussain T., Hayes W., Scarr E., Kitsoulis S., Hill C., Opeskin K., and Copolov D.L. Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 72 4 (1999) 1593-1599
28. De Deurwaerdere P., Navailles S., Berg K.A., Clarke W.P., and Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24 13 (2004) 3235-3241
29. De Deurwaerdere P., and Spampinato U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73 3 (1999) 1033-1042
30. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 47 (2005) 10831-10843
31. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38 8 (1999) 1195-1205
32. Doherty M.D., and Pickel V.M. Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 864 2 (2000) 176-185
33. Dunlop J., Marquis K.L., Lim H.K., Leung L., Kao J., Cheesman C., and Rosenzweig-Lipson S. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev. 12 3-4 (2006) 167-177
34. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49 (1992) 538-544
35. Fiorella D., Helsley S., Rabin R.A., and Winter J.C. The interactions of typical and atypical antipsychotics with the (-)2,5-dimethoxy-4-methamphetamine (DOM) discriminative stimulus. Neuropharmacology 34 (1995) 1297-1303
36. Fischman A.J., Bonab A.A., Babich J.W., Alpert N.M., Rauch S.L., Elmaleh D.R., Shoup T.M., Williams S.A., and Rubin R.H. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharmacol. Exp. Ther. 279 2 (1996) 939-947
37. Frantz K.J., Hansson K.J., Stouffer D.G., and Parsons L.H. 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 42 (2002) 170-180
38. 6 receptor mRNA levels in rat brain. Schizophr. Res. 38 (1999) 7-12
39. Gardell L.R., Vanover K.E., Pounds L., Johnson R.W., Barido R., Anderson G.T., Veinbergs I., Dyssegaard A., Brunmark P., Tabatabaei A., Davis R.E., Brann M.R., Hacksell U., and Bonhaus D.W. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 322 2 (2007) 862-870
40. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23 (1996) 164-173
41. 6 receptor-like material in the rat central nervous system. Brain Res. 746 (1997) 207-219
42. Gewirtz J.C., and Marek G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23 5 (2000) 569-576
43. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 156 2-3 (2001) 117-154
44. Gleason S.D., and Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129 (1997) 79-84
45. Grayson B., Idris N.F., and Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 184 1 (2007) 31-38
46. Gresch P.J., Strickland L.V., and Sanders-Bush E. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114 3 (2002) 707-713
47. 2/3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 5 (2006) 1027-1035
48. Gudelsky G.A., Koenig J.I., Simonovic M., Koyama T., Ohmori T., and Meltzer H.Y. Differential effects of haloperidol, clozapine and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J. Neural. Transm. 68 (1987) 227-240
49. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., and Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34 (1993) 702-712
50. Hagiwara, H., Fujita, Y., Ishima, T., Kunitachi, S., Shirayama, Y., Iyo, M. and Hashimoto, K. (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT(1A) receptors. Eur. Neuropsychopharmacol., E pub ahead of print.
51. 6 receptors. Neuropsychopharmacology 21 (1999) 68S-76S
52. Hasler F., Grimberg U., Benz M.A., Huber T., and Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172 2 (2004) 145-156
53. Herrick-Davis K., Grinde E., and Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther. 295 1 (2000) 226-232
54. 2 adrenoceptor antagonism. Neuropsychopharmacology 17 (1997) 44-55
55. 2C receptors after chronic treatment. Psychopharmacol. 157 2 (2001) 180-187
56. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W., Wasan K., and Procyshyn R. Clozapine and Risperidone Enhancement (CARE) Study Group Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 354 (2006) 472-482
57. Hong C.J., Yu Y.W., Lin C.H., and Tsai S.J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 349 (2003) 206-208
58. 2C receptor antagonism enhances risperidone-induced dopamine (DA) efflux in rat medial prefrontal cortex (mpfc) and diminishes it in the nucleus accumbens (NAC). Neurosci. Abs. 914.10.
59. Huber G., Maerz W., Martin J.R., Malherbe P., Richards J.G., Sueoka N., Ohm T., and Hoffmann M.M. Characterization of transgenic mice expressing apolipoprotein E4 (C112R) and apolipoprotein E4 (L28P; C112R). Neuroscience 101 (2000) 211-218
60. Hurlemann R., Matusch A., Kuhn K.U., Berning J., Elmenhorst D., Winz O., Kolsch H., Zilles K., Wagner M., Maier W., and Bauer A. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl.) 195 4 (2008) 579-590
61. Ichikawa J., Dai J., O'Laughlin I.A., Dai J., Fowler W., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs selectively increase acetylcholine release in rat medial prefrontal cortex, nucleus accumbens and striatum. Neuropsychopharmacology 26 3 (2002) 325-339
62. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 5 (2001) 1521-1531
63. Ichikawa J., Kuroki T., Dai J., and Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur. J. Pharmacol. 351 (1998) 163-171
64. 1A receptor agonism. Brain Res. 956 2 (2002) 349-357
65. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res. 698 (1995) 204-208
66. Ichikawa J., and Meltzer H.Y. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858 2 (2000) 252-263
67. 2 receptors induced by haloperidol in rat striatum. Eur. J. Pharmacol. 321 (1997) 163-169
68. Jakab R.L., and Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA 95 (1998) 735-740
69. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., and Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8 (1993) 315-336
70. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57 (1995) PL103-PL107
71. 2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25 (2000) 161-166
72. 2 receptor occupancy. Arch. Gen. Psychiatry 57 (2000) 553-559
73. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Schizophr. Res. 76 2-3 (2005) 357-358
74. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., and Meltzer H.Y. Occupancy of striatal and extrastriatal dopamine D(2)/D(3) receptors by olanzapine and haloperidol. Neuropsychopharmacology 30 12 (2005) 2283-2289
75. 2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31 (2006) 1991-2001
76. 6 serotonin receptor. J. Neurochem. 66 (1996) 47-56
77. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 2 (1999) 774-781
78. 6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 (2004) 158-164
79. 6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol. Biochem. Behav. 75 2 (2003) 281-288
80. Li Z., Huang M., Ichikawa J., Dai J., and Meltzer H.Y. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30 11 (2005) 1986-1995
81. 2A/2C inverse agonist ACP103 on dopamine (DA) efflux in rat brain. Neurosci. Abs., 914.8.
82. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
83. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 30 12 (2005) 2169-2179
84. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947 (2002) 157-165
85. Linden A.M., Vaisanen J., Lakso M., Nawa H., Wong G., and Castren E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J. Mol. Neurosci. 14 (2000) 27-37
86. 2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 33 2 (2008) 298-304
87. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161 (2004) 818-825
88. Mamo D.C., Uchida H., Vitcu I., Barsoum P., Gendron A., Goldstein J., and Kapur S. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J. Clin. Psychiatry 69 1 (2008) 81-86
89. Marder S.R. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151 (1994) 825-835
90. Martin P., Waters N., Waters S., Carlsson A., and Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M 100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335 2-3 (1997) 107-116
91. 2C receptor selective agonist with preclinical antipsychotic activity. J. Pharmacol. Exp. Ther. 320 (2007) 486-496
92. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., Cola P., Howard A., Badri F., Nothen M.M., Kalow W., and Kennedy J.L. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19 (1998) 123-132
93. 2 receptor density in rat cerebral cortex. Life Sci. 45 15 (1989) 1397-1406
94. Matsumoto M., Togashi H., Mori K., Ueno K., Miyamoto A., and Yoshioka M. Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 383 (1999) 39-48
95. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3 2 (1995) 4-75
96. Meltzer H.Y. Mechanism of action of atypical antipsychotic drugs. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 819-832
97. Meltzer H.Y., Arvanitis L., Bauer D., Rein W., and Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161 6 (2004) 975-984
98. Meltzer H.Y., and Fatemi S.H. The role of serotonin in schizophrenia and the mechanism of action on anti-psychotic drugs. In: Kane J.M., Moller H.J., and Awouters F. (Eds). Serotonergic Mechanisms in Antipsychotic Treatment (1996), Marcel Dekker, New York 77-107
99. Meltzer H.Y., and Maes M. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res. 58 (1995) 89-98
100. i values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
101. Meltzer H.Y., and Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 43 (1991) 587-604
102. Meneses A. Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation. Behav. Brain Res. 118 (2001) 107-110
103. (2A/2B/2C) receptors on memory formation: simple agonism, antagonism, or inverse agonism?. Cell. Mol. Neurobiol. 22 5-6 (2002) 675-688
104. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286 (1998) 1341-1355
105. Millan M.J., Gobert A., Roux S., Porsolt R., Meneses A., Carli M., Di Cara B., Jaffard R., Rivet J.M., Lestage P., Mocaer E., Peglion J.L., and Dekeyne A. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. J. Pharmacol. Exp. Ther. 311 (2004) 190-203
106. 6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 52 1 (2004) 20-28
107. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychatic drugs. Mol. Psychiatry 10 1 (2005) 79-104
108. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54 5 (1990) 1755-1760
109. Monsma Jr. F.J., Shen Y., Ward R.P., Hamblin M.W., and Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43 (1993) 320-327
110. Newman-Tancredi A., Cussac D., and Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs 8 7 (2007) 539-554
111. 1A receptors: a [35S]GTPgammaS binding study. Eur. J. Pharmacol. 355 (1998) 245-256
112. Ngan E.T., Yatham L.N., Ruth T.J., and Liddle P.F. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F]setoperone. Am. J. Psychiatry 157 (2000) 1016-1018
113. 2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur. J. Pharamacol. 358 (1998) 111-116
114. Niswender C.M., Copeland S.C., Herrick-Davis K., Emeson R.B., and Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem. 274 14 (1999) 9472-9478
115. Olijslagers J.E., Perlstein B., Werkman T.R., McCreary A.C., Siarey R., Kruse C.G., and Wadman W.J. The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro. Eur. J. Pharmacol. 520 1-3 (2005) 77-85
116. 4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Brit. J. Pharmacol. 121 3 (1997) 515-525
117. 2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). J. Pharmacol. Exp. Ther. 282 1 (1997) 56-63
118. Parada M.A., Hernandez L., Puig de Parada M., Rada P., and Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281 (1997) 582-588
119. Pazos A., Probst A., and Palacios J.M. Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21 (1987) 123-139
120. Pehek E.A., McFarlane H.G., Maguschak K., Price B., and Pluto C.P. M100907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888 1 (2001) 51-59
121. Pouzet B., Didriksen M., and Arnt J. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav. 71 4 (2002) 635-643
122. Prinssen E.P., Ellenbroek B.A., and Cools A.R. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol. 262 (1994) 167-170
123. Prinssen E.P., Kleven M.S., and Koek W. Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacology 128 (1996) 191-197
124. 2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 6 (2005) 1021-1028
125. Richtand N.M., Welge J.A., Logue A.D., Keck Jr. P.E., Strakowski S.M., and McNamara R.K. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32 8 (2007) 1715-1726
126. 6 receptor antagonist. J. Med. Chem. 46 7 (2003) 1273-1276
127. Rinaldi-Carmona M., Congy C., Simiand J., Oury-Donat F., Soubrie P., Breliere J.C., and Le Fur G. Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain. Mol. Pharmacol. 3 1 (1993) 84-89
128. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 158 (2001) 114-119
129. 6 antagonist SB-271046. Br. J. Pharmacol. 127 (1999) 22
130. 1A receptor activation. Eur. J. Pharmacol. 338 (1997) R3-R5
131. 1C receptors. J. Pharmacol. Exp. Ther. 260 (1992) 1361-1365
132. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma Jr. F.J., Shen Y., Meltzer H.Y., and Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268 (1994) 1403-1410
133. 6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193 (1993) 268-276
134. Santana N., Bortolozzi A., Serrats J., Mengod G., and Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 14 10 (2004) 1100-1109
135. 2A receptors in antipsychotic activity. Life Sci. 56 (1995) 2209-2222
136. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
137. Shipley, J. (1998) M100907 phase IIB trial Hoechst Marion Roussel Conference on M100907, West Palm Beach, Florida.
138. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 5 (2002) 583-594
139. 6 receptors: functional correlates and potential therapeutic indications. Behav. Pharmacol. 10 (1999) S86-S87
140. Sodhi M.S., Airey D.C., Lambert W., Burnet P.W., Harrison P.J., and Sanders-Bush E. A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol. Pharmacol. 68 3 (2005) 711-719
141. 2C receptor gene. Neuroreport 7 1 (1995) 169-172
142. Stahl S.M., and Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr. Med. Chem. 11 3 (2004) 313-327
143. Stean T.O., Hirst W.D., Thomas D.R., Price G.W., Rogers D., Riley G., Bromidge S.M., Serafinowska H.T., Smith D.R., Bartlett S., Deeks N., Duxon M., and Upton N. Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist. Pharmacol. Biochem. Behav. 71 (2002) 645-654
144. Swainston Harrison T., and Perry C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64 15 (2004) 1715-1736
145. Talvik M., Nordstrom A.L., Nyberg S., Olsson H., Halldin C., and Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and (11)C]FLB 457. Am. J. Psychiatry 158 6 (2001) 926-930
146. Tamminga C.A. Partial dopamine agonists in the treatment of psychosis. J. Neural. Transm. 109 3 (2002) 411-420
147. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 31 (1998) 13-17
148. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry 155 4 (1998) 505-508
149. Ukai W., Ozawa H., Tateno M., Hashimoto E., and Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J. Neural. Transm. 111 6 (2004) 667-681
150. 2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17 (1997) 2785-2795
151. 2A receptor inverse agonist. J. Pharmacol. Exp. Ther. 317 2 (2006) 910-918
152. 2 receptor antagonist ketanserin. Eur. J. Pharmacol. 287 (1995) 201-205
153. Verhoeff N.P., Meyer J.H., Kecojevic A., Hussey D., Lewis R., Tauscher J., Zipursky R.B., and Kapur S. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res. 99 (2000) 123-135
154. 2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32 9 (2007) 1876-1887
155. Wadenberg M.L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural. Transm. Gen. Sect. 89 (1992) 49-59
156. Wadenberg M.L., and Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural. Transm. Gen. Sect. 83 (1991) 43-53
157. Wadenberg M.L., Hicks P.B., Richter J.T., and Young K.A. Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100907. Biol. Psychiatry 44 (1998) 508-515
158. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 34 (1995) 495-499
159. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., Harvey S.C., Donohue E., Hansen H.C., Andersson C.M., Spalding T.A., Gibson D.F.C., Krebs-Thomson K., Powell S.B., Geyer M.A., Hacksell U., and Brann M.R. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299 (2001) 268-276
160. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472
161. 6 receptor antagonist, Ro 04-6790. Psychopharmacology 170 (2003) 358-867
162. Yamada S., Harano M., Annoh N., Nakamura K., and Tanaka M. Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol. Psychiatry 46 (1999) 832-838
163. Youngren K.D., Inglis F.M., Pivirotto P.J., Jedema H.P., Bradberry C.W., Goldman-Rakic P.S., Roth R.H., and Moghaddam B. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20 5 (1999) 403-412
164. Youngren K.D., Moghaddam B., Bunney B.S., and Roth R.H. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci. Lett. 165 1-2 (1994) 41-44
165. Zahorodna A., Bobula B., Grzegorzewska M., Tokarski K., and Hess G. The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex. J. Physiol. Pharmacol. 55 2 (2004) 371-379
166. Zocchi A., Fabbri D., and Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci. Lett. 387 3 (2005) 157-161